Creo Medical to Announce Interim Results and Host Investor Presentation

An update from Creo Medical ( (GB:CREO) ) is now available.

Creo Medical Group plc announced it will release its unaudited interim results for the first half of 2025 on September 22, 2025. The company will host a live online presentation for investors on September 24, 2025, to discuss these results, reflecting its commitment to transparency and engagement with shareholders. This announcement underscores Creo’s ongoing efforts to strengthen its market position in the medical device industry, particularly in the field of minimally invasive surgical endoscopy.

The most recent analyst rating on (GB:CREO) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.

Spark’s Take on GB:CREO Stock

According to Spark, TipRanks’ AI Analyst, GB:CREO is a Neutral.

Creo Medical’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis provides a mixed outlook with some short-term positive signals, but the valuation remains poor due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on GB:CREO stock, click here.

More about Creo Medical

Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on enhancing surgical endoscopy for pre-cancer and cancer patients through its advanced energy technology, CROMA powered by Kamaptive, which integrates multi-modal energy sources for improved surgical outcomes.

Average Trading Volume: 490,823

Technical Sentiment Signal: Strong Sell

Current Market Cap: £53.21M

For an in-depth examination of CREO stock, go to TipRanks’ Overview page.